Tibsovo (ivosidenib) [package insert]. FDA.

Regulatory approval published by the Food and Drug Administration. Deprecated

Citation

Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 6, 2026.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes. 5

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (1) IDH1 p.R132C Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132G Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132H Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132L Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132S Myelodysplastic Syndromes Ivosidenib